Teva Pharmaceutical Industries Ltd (TEVA) 54.02 $TEVA
Teva Raises Q2 Guidance; to Unveil 2016-2019 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:47AM CDT
Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.
IPXL: 31.54 (+0.22), AGN: 245.43 (+5.73), MYL: 45.87 (+0.71), TEVA: 54.02 (+1.56)
After Yesterday's Rally of 1.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jul 11, 12:59PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.66 to a high of $51.63. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $51.10 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 54.02 (+1.56)
Look for Shares of Teva Pharmaceutical Industries to Potentially Pullback after Yesterday's 1.03% Rise
Comtex SmarTrend(R) - Mon Jul 11, 12:57PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.66 to a high of $51.63. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $51.10 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 54.02 (+1.56)
NeuroDerm Announces Additions to Management Team
GlobeNewswire - Wed Jul 06, 10:02AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chief Operating Officer and Eran Shor as Vice President (VP) Devices.
TEVA: 54.02 (+1.56), NDRM: 16.86 (-0.07)
Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick(R) Inhalers
BusinessWire - Tue Jun 28, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug applications (NDAs) for two products for adolescent and adult patients with asthma. The first, fluticasone propionate/salmeterol, is a fixed-dose combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via Teva's RespiClick(R) breath-actuated, multi-dose dry powder inhaler (MDPI). The second, fluticasone propionate, is an ICS monotherapy also delivered via the RespiClick(R) device.
TEVA: 54.02 (+1.56)
Teva's Cinqaero Gets Positive CHMP View, Decision in 2H16
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 7:10AM CDT
Teva's (TEVA) asthma treatment, Cinqaero, which is already available in the U.S., got a positive CHMP opinion.
AGN: 245.43 (+5.73), PFE: 36.35 (+0.11), TEVA: 54.02 (+1.56), AMPH: 17.48 (+0.14)
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 245.43 (+5.73), PFE: 36.35 (+0.11), TEVA: 54.02 (+1.56), AMPH: 17.48 (+0.14)
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta(R) (Exenatide Injection) in the United States
BusinessWire - Thu Jun 23, 7:30AM CDT
Teva Pharmaceuticals USA, Inc., (NYSE and TASE:TEVA) today announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA(R) (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA(R) described in Teva's ANDA No. 205984 in the United States.
TEVA: 54.02 (+1.56)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 31.54 (+0.22), AGN: 245.43 (+5.73), TEVA: 54.02 (+1.56), AMPH: 17.48 (+0.14)
Valeant Pharmaceuticals, Teva, Red Hat, Schlumberger, and Southwestern Energy Company and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jun 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, TEVA, RHT, SLB and SWN.
VRX: 24.02 (+0.80), RHT: 74.33 (+0.42), TEVA: 54.02 (+1.56), SWN: 13.96 (-0.24), SLB: 78.76 (-0.89)
Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson's Disease and Movement Disorders
BusinessWire - Mon Jun 20, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data for SD-809 (deutetrabenazine) tablets will be presented at the 20th International Congress of Parkinson's Disease and Movement Disorders (MDS) in Berlin, June 19-23, 2016.
TEVA: 54.02 (+1.56)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Thu Jun 16, 12:27PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.62 to a high of $52.16. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $52.19 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 54.02 (+1.56)
Teva Pharmaceutical Industries Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Thu Jun 16, 12:25PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.62 to a high of $52.16. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $52.19 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 54.02 (+1.56)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 245.50 (+5.80), SGNT: 21.65 (-0.02), TEVA: 54.02 (+1.56)
Teva stops selling migraine patch after reports of burns
AP - Mon Jun 13, 11:25AM CDT
NEW YORK (AP) — Teva Pharmaceutical said Monday that it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied. The company advised that anyone who has its patch should not use it.
TEVA: 54.02 (+1.56)
Teva Announces Voluntary Suspension of Marketing for ZECUITY(R) in the U.S.
BusinessWire - Mon Jun 13, 7:00AM CDT
Teva Pharmaceutical Industries, Ltd. (NYSE and TASE:TEVA) announced today that it will voluntarily suspend sales, marketing and distribution of ZECUITY(R) (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with ZECUITY, and is working in full cooperation with the U. S. Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
TEVA: 54.02 (+1.56)
Teva Announces Favorable Court Ruling in TREANDA(R) (bendamustine hydrochloride) Patent Infringement Litigation
BusinessWire - Fri Jun 10, 1:20PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company's patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva's TREANDA(R) (bendamustine hydrochloride) for Injection.
TEVA: 54.02 (+1.56)
Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 36.35 (+0.11), RTRX: 18.46 (-0.11), TEVA: 54.02 (+1.56), BMY: 76.47 (+0.27)
Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA(TM) ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology
BusinessWire - Tue Jun 07, 2:33PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 to recommend approval of VANTRELA(TM) ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. VANTRELA ER is an extended-release formulation of hydrocodone bitartrate with Teva's proprietary abuse deterrence technology.
TEVA: 54.02 (+1.56)
Teva to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Tue Jun 07, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Jefferies Healthcare Conference. Mike Derkacz will present on Thursday, June 9, 2016 at 1:30 PM ET.
TEVA: 54.02 (+1.56)
Teva Raises Q2 Guidance; to Unveil 2016-2019 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:47AM CDT
Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.
IPXL: 31.54 (+0.22), AGN: 245.43 (+5.73), MYL: 45.87 (+0.71), TEVA: 54.02 (+1.56)
After Yesterday's Rally of 1.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jul 11, 12:59PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.66 to a high of $51.63. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $51.10 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 54.02 (+1.56)
Look for Shares of Teva Pharmaceutical Industries to Potentially Pullback after Yesterday's 1.03% Rise
Comtex SmarTrend(R) - Mon Jul 11, 12:57PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.66 to a high of $51.63. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $51.10 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 54.02 (+1.56)
NeuroDerm Announces Additions to Management Team
GlobeNewswire - Wed Jul 06, 10:02AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chief Operating Officer and Eran Shor as Vice President (VP) Devices.
TEVA: 54.02 (+1.56), NDRM: 16.86 (-0.07)
Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick(R) Inhalers
BusinessWire - Tue Jun 28, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug applications (NDAs) for two products for adolescent and adult patients with asthma. The first, fluticasone propionate/salmeterol, is a fixed-dose combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via Teva's RespiClick(R) breath-actuated, multi-dose dry powder inhaler (MDPI). The second, fluticasone propionate, is an ICS monotherapy also delivered via the RespiClick(R) device.
TEVA: 54.02 (+1.56)
Teva's Cinqaero Gets Positive CHMP View, Decision in 2H16
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 7:10AM CDT
Teva's (TEVA) asthma treatment, Cinqaero, which is already available in the U.S., got a positive CHMP opinion.
AGN: 245.43 (+5.73), PFE: 36.35 (+0.11), TEVA: 54.02 (+1.56), AMPH: 17.48 (+0.14)
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 245.43 (+5.73), PFE: 36.35 (+0.11), TEVA: 54.02 (+1.56), AMPH: 17.48 (+0.14)
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta(R) (Exenatide Injection) in the United States
BusinessWire - Thu Jun 23, 7:30AM CDT
Teva Pharmaceuticals USA, Inc., (NYSE and TASE:TEVA) today announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA(R) (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA(R) described in Teva's ANDA No. 205984 in the United States.
TEVA: 54.02 (+1.56)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 31.54 (+0.22), AGN: 245.43 (+5.73), TEVA: 54.02 (+1.56), AMPH: 17.48 (+0.14)
Valeant Pharmaceuticals, Teva, Red Hat, Schlumberger, and Southwestern Energy Company and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jun 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, TEVA, RHT, SLB and SWN.
VRX: 24.02 (+0.80), RHT: 74.33 (+0.42), TEVA: 54.02 (+1.56), SWN: 13.96 (-0.24), SLB: 78.76 (-0.89)
Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson's Disease and Movement Disorders
BusinessWire - Mon Jun 20, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data for SD-809 (deutetrabenazine) tablets will be presented at the 20th International Congress of Parkinson's Disease and Movement Disorders (MDS) in Berlin, June 19-23, 2016.
TEVA: 54.02 (+1.56)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Thu Jun 16, 12:27PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.62 to a high of $52.16. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $52.19 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 54.02 (+1.56)
Teva Pharmaceutical Industries Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Thu Jun 16, 12:25PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.62 to a high of $52.16. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $52.19 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 54.02 (+1.56)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 245.50 (+5.80), SGNT: 21.65 (-0.02), TEVA: 54.02 (+1.56)
Teva stops selling migraine patch after reports of burns
AP - Mon Jun 13, 11:25AM CDT
NEW YORK (AP) — Teva Pharmaceutical said Monday that it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied. The company advised that anyone who has its patch should not use it.
TEVA: 54.02 (+1.56)
Teva Announces Voluntary Suspension of Marketing for ZECUITY(R) in the U.S.
BusinessWire - Mon Jun 13, 7:00AM CDT
Teva Pharmaceutical Industries, Ltd. (NYSE and TASE:TEVA) announced today that it will voluntarily suspend sales, marketing and distribution of ZECUITY(R) (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with ZECUITY, and is working in full cooperation with the U. S. Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
TEVA: 54.02 (+1.56)
Teva Announces Favorable Court Ruling in TREANDA(R) (bendamustine hydrochloride) Patent Infringement Litigation
BusinessWire - Fri Jun 10, 1:20PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company's patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva's TREANDA(R) (bendamustine hydrochloride) for Injection.
TEVA: 54.02 (+1.56)
Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 36.35 (+0.11), RTRX: 18.46 (-0.11), TEVA: 54.02 (+1.56), BMY: 76.47 (+0.27)
Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA(TM) ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology
BusinessWire - Tue Jun 07, 2:33PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 to recommend approval of VANTRELA(TM) ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. VANTRELA ER is an extended-release formulation of hydrocodone bitartrate with Teva's proprietary abuse deterrence technology.
TEVA: 54.02 (+1.56)
Teva to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Tue Jun 07, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Jefferies Healthcare Conference. Mike Derkacz will present on Thursday, June 9, 2016 at 1:30 PM ET.
TEVA: 54.02 (+1.56)
